Nouscom appoints Loredana Siani as CTO following €120M Series D funding
1 report, 1 independent
Updated Nov 2
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Nouscom promoted Loredana Siani to Chief Technology Officer to support the advancement of NOUS-209 in Lynch Syndrome. This promotion follows the company securing €120 million in Series D financing. Loredana Siani, who completed her MBA at Luiss Business School and her Ph.D. in Naples, will lead the company’s Chemistry, Manufacturing, and Controls.
From manilatimes.net
Why it matters
The Series D financing provides capital to move NOUS-209 into a registration-enabling clinical trial. The appointment of Loredana Siani to lead manufacturing and technical operations supports the company's ability to scale its next-generation immunotherapy program.
From manilatimes.net
Who's involved
- Loredana SianiPromoted to Chief Technology Officer at Nouscom, leading manufacturing and technical operations.
Keep exploring
The entities involved
-
Loredana Siani
researcher
Nothing else this week.
-
Luiss Business School
school in Italy
Nothing else this week.